We provide you with 20 years of free, institutional-grade data for MORF stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of MORF. Explore the full financial landscape of MORF stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|
The information provided in this report about MORF stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Morphic Holding, Inc(NASDAQ:MORF) 
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a47-specific integrin inhibitor affec...
Website: http://www.morphictx.com
Founded: 2014
IPO Price: $15 (Jun 27, 2019)
Full Time Employees: 87
CEO: Praveen P. Tipirneni
Sector: Healthcare
Industry: Biotechnology